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SUMMARY
The SCID-hu Thy/Liv mouse is a model for the analysis of human thymopoiesis. It has been 
constructed by engrafting fragments of human fetal liver and thymus into the immunodeficient 
C.B-17 scid/scid (SCID) mouse. The resulting ‘Thy/Liv’ organ promotes long-term differentiation 
of human T cells. Given the apparently normal physiology of the SCID-hu Thy/Liv organ, it has 
been used to explore the pathophysiologic mechanisms of HIV-1 infection in vivo, and to test 
therapeutic modalities such as anti-HIV-1 drugs and haematopoietic stem cell (HSC)-based gene 
therapy. In this review, I will summarise what we have learned from the SCID-hu Thy/Liv model, 
with a focus on recent findings in HIV-1 replication and therapy. Unique HIV-1 determinants have 
been identified which are required for replication in the Thy/Liv organ but not for replication in 
PBMC or in T cell lines in vitro. The mechanism of HIV-1 induced thymus depletion is not clear. 
It is correlated with high levels of HIV-1 replication. Both direct and indirect mechanisms may be 
involved. In addition to preclinical evaluation of anti-HIV-1 drugs, the SCID-hu Thy/Liv mouse 
has also been successfully used to test the feasibility of HSC-based gene therapy.
A number of improved SCID-hu models have been constructed to meet different requirements. 
Using these SCID-hu Thy/Liv models, current/future efforts will provide insightful information 
for understanding pathogenesis and designing therapeutic interventions against HIV-1 infection in 
humans, especially in paediatric patients.
INTRODUCTION
It has become increasingly clear that the pathophysiologic correlates leading to T cell 
depletion during HIV-1 disease may be clarified by direct evaluation of interactions between 
the virus and defined haematolymphoid organs.1,2 Though not well studied during HIV-1 
infection, the thymus has been implicated as a site of early viral replication3–8 and thymic 
organs from HIV-1 infected fetuses and paediatric patients show profound parenchymal 
damage and involution.5,6,9,10 More significantly, a strong correlation of HIV induced 
thymus dysfunction has been established with faster AIDS progression in paediatric 
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patients.11 In addition, early thymus destruction appears to be a common feature of other 
lentivirus diseases in FIV-infected cats12 and SIV-infected monkeys.13
In the thymus, where most T cells are derived, CD4 is present not only on mature 
(CD3+CD4+CD8−) T cells and macrophages, but also on less mature thymocytes 
(CD3−/low CD4+CD8+) and intrathymic progenitor (CD3−CD4+CD8−) cells.14,15 Since 
the thymus organ is difficult to study in human subjects, a small animal model (SCID-hu 
Thy/Liv mouse) for the analysis of human thymopoiesis has been constructed by engrafting 
fragments of human fetal liver and thymus into the immunodeficient C.B-17 scid/scid 
(SCID) mouse.16 The resulting ‘Thy/Liv’ organ promotes longterm differentiation of human 
T cells in a manner which appears physiologically normal.17,18 Thymocyte subpopulations 
are represented within the organ in expected proportions, a normal T cell receptor Vfl 
repertoire is displayed,19,20 and tolerance is induced towards both ‘self’ major 
histocompatibility antigens and exogenously provided superantigens.21,22
Given the apparently normal physiology of the SCID-hu Thy/Liv organ, we and others23–26 
have used this model to explore the pathophysiologic mechanisms of HIV-1 infection in 
vivo. In this review, I will summarise what we have learned from the SCID-hu Thy/Liv 
model, with a focus on recent findings in HIV-1 replication and therapy. A number of 
reviews of earlier reports have been published.27,28 A different humanised SCID model, hu-
PBL-SCID,29 which is transplanted with mature human PBMC, will not be covered here.
THE SCID-HU THY/LIV MOUSE AS A MODEL FOR PRIMARY HIV-1 
INFECTION AND PATHOGENESIS IN THE HUMAN THYMUS
In contrast to in vitro models of HIV-1 infection, the SCID-hu Thy/Liv mouse provides an 
intact human lymphoid organ for HIV-1 infection. Multiple cell types are present and, most 
importantly, most target cells are in their physiological resting stage. In addition, normal T 
cell development and maturation occur in the Thy/Liv organ over 12 months after 
transplantation.17,18
The organ system is permissive for infection with primary HIV-1 isolates.30 Both 
macrophages and T cells are infected in the Thy/Liv organ. Most T cell line-adapted HIV-1 
strains, however, failed to replicate efficiently.31 The infection proceeds in a dose- and time-
dependent manner and is suppressed by in vivo administration of nucleoside analogues such 
as zidovudine (AZT).32
In an attempt to analyse AZT resistant mutants arising during in vivo selection, multiple 
rounds of infection of the Thy/Liv organ in the presence of increasing concentrations of 
AZT have failed to generate AZT-resistant HIV-1 mutants (J. McCune and H. Kaneshima., 
personal communication). This is consistent with the finding that very few mutations have 
accumulated during the infection process.33 Thus HIV-1 replication in this model reflects a 
low level, primary infection in the absence of immune selection.
After intra-organ inoculation of the SCID-hu Thy/Liv with HIV-1 (Figure. 1), HIV-1 
replication reaches high levels followed by depletion of CD4+ thymocytes with an inversion 
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of the CD4/CD8 ratio.23,24,34 CD4+CD8+ thymocytes, which comprise 80–85% of total 
thymocytes, are significantly depleted about 1 week after HIV-1 reaches peak infection 
(Figure 2).24,35 In addition, a more accelerated pace of replication and thymocyte depletion 
is observed with rapidly replicating, syncytium-inducing (SI) virus isolated from AIDS 
patients than with slowly replicating, non-syncytium-inducing (NSI) virus isolated from the 
same patients before AIDS development, or from long term non-progressor patients.36,37 
Thus, the Thy/Liv organ provides a relevant in vivo model to evaluate primary HIV-1 
replication and pathogenicity.
ANALYSIS OF HIV-1 FACTORS UNIQUELY REQUIRED FOR REPLICATION 
IN THE THY/LIV ORGAN
Studies of HIV-1 accessory genes in the SCID-hu Thy/Liv model
As is observed in the SIV-infected rhesus macaque,38 replication and pathologic effects (e.g. 
thymocyte depletion) of HIV-1 (both NL4–3 and JRCSF) in the SCID-hu mouse are 
dependent upon an intact nef open reading frame39 Analysis of the other HIV-1 accessory 
genes such as vpr, vpu and vif has demonstrated that, unlike in tissue cultures, mutations in 
these genes significantly slowed down the replication and cytopathic effects of HIV-1-
NL4-3.40
A close correlation between the levels of HIV-1 replication and thymocyte depletion has 
been established (Table 1). Thus, NL4-3, JD, EW and primary SI isolates replicated to high 
levels in about 2–3 weeks post inoculation (wpi) and lead to early thymocyte depletion at 
about 3–4 wpi. JRCSF, NL4-3 mutants (nef-, vpu- or vif-) and primary NSI isolates 
replicated to peak levels in about 5–6 weeks and significant thymocyte depletion occurred at 
about 7–8 weeks post infection. In addition, high input HIV-1 accelerated both HIV-1 
replication and its associated thymocyte depletion.40 Therefore, prolonged presence of high 
viral replication is required to cause thymocyte depletion.
HIV-1 env determinants required for efficient replication in the Thy/Liv organ
Comparison of ‘attenuated’ HIV-1 isolates with ‘pathogenic’ ones in vitro and in vivo 
should help to identify important viral determinants for replication and pathogenesis in vivo. 
The Lai/IIIB isolate and its associated infectious molecular clones (e.g. HXB2) were found 
to infect T cell lines such as H9.41 When a laboratory worker was accidentally infected by 
Lai/IIIB, however, HIV-1 was isolated only from inoculation of primary PBMC, but not 
from T cell lines.42 The SCID-hu Thy/Liv model was used to study the replication of HXB2 
and of HXB2 recombinant viruses with HIV-1 fragments isolated from the infected 
laboratory worker.43 HXB2 showed no or very low levels of replication in the Thy/Liv 
organ. Replacement of its subgenomic fragment encoding the envelope gene with a 
corresponding fragment from the LW87-1 isolate generated a recombinant virus 
(HXB2/LW) which replicated actively in SCID-hu mice.
The specific env determinants have been mapped to the V1–V3 regions of the HIV-1 
genome. Six unique mutations in the V3 loop region have been identified which contribute 
to most of its increased replication in vivo. These changes affected target cell tropism and/or 
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overall infectivity of the virus. However, HXB2/LW showed no enhanced replication 
activity in PBMC. Thus, altered or expanded host cell range may contribute to its enhanced 
replication in the Thy/Liv organ.
The unique structural determinants in HIV-1 appear to be necessary for infectivity in vivo, 
but not in PBMC or in immortalised T cell lines. Interestingly, the relevant changes did not 
affect the nef gene, previously implicated for pathogenicity of SIV in rhesus macaques,38 or 
of HIV-1 in SCID-hu mice.39,40 The vpu and vpr genes, which have also been reported to 
affect HIV-1 replication in SCID-hu Thy/Liv mice,40 of HXB2/LW also remain defective. 
Thus, unique features of the V3 region of env that are necessary for infection of thymic 
target cells are revealed by phenotypic and molecular analyses of HIV-1 isolates in the 
SCID-hu Thy/Liv mouse.
A variation of the SCID-hu Thy/Liv model which transplants more human tissues has been 
developed.25 In this model, HIV-1 infection can be initiated by intraperitoneal inoculation.44 
However, the Lai/IIIB isolate appears to infect the Thy/Liv organ in this model and leads to 
thymus depletion. The difference may be due to its long duration (6 months) of infection 
and/or to activation of human thymocytes in this model by some unknown mechanisms.
MECHANISMS OF HIV-1 INDUCED THYMUS DEPLETION
HIV-1 replication in the Thy/Liv organ leads to thymocyte depletion with a preference for 
CD4+ thymocytes. As mentioned above, a close correlation exists between levels of HIV-1 
replication and thymocyte depletion (Table 1). Kinetic analysis indicated that thymocyte 
depletion occurs about 1–2 weeks after HIV-1 peak replication is achieved (Figure 2). This 
indicates that high levels of viral replication are required to lead to thymus depletion. Both 
viral encoded proteins and host factors may be involved. The SCID-hu Thy/Liv mouse has 
been used to address the following questions regarding HIV-1 induced thymus depletion.
How do thymocytes die in response to HIV-1 infection in the Thy/Liv organ?
Apoptosis has been associated with HIV-1 induced T cell death both in vitro and in 
vivo.45–49 It appears to be associated, at least partly, with HIV-1 induced thymocyte 
depletion in the Thy/Liv organ. Morphologically, some thymocytes with condensed nuclei 
are detected in HIV-1 infected Thy/Liv organs by thin section light microscopy and by 
electron microscopy.24 Biochemically, partial chromosomal loss (detected by propidium 
iodide staining)24 and DNA strand breaks (detected by terminal deoxynucleotide transferase 
labelling)35 are associated with HIV-1 induced thymocyte depletion, although the 
characteristic chromosomal DNA ladder associated with most forms of apoptosis is not 
consistently observed (Su, Bonyhadi, Kaneshima and McCune, unpublished observation). 
Experiments performed by a different research group using the Thy/Liv model have failed to 
demonstrate evidence of significant levels of apoptosis during HIV-1 induced thymocyte 
depletion. Necrosis appears to be the major mechanism of HIV-1 induced T cell death (J. 
Zack, personal communication). Differences in experimental procedures and in animal 
maintenance conditions may contribute to the discrepancy.
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Are all dead or dying thymocytes directly infected with HIV-1?
Regardless of how thymocytes die after HIV-1 infection, a very important question is 
whether direct infection is required for the thymocyte to die. The replication level of HIV-1 
in the Thy/Liv organ is relatively low. At peak times, about 10% thymocytes are infected as 
measured by PCR detection of proviral DNA.23,33–35,39,40,43 This is consistent with lack of 
significant mutation during infection33 and failure to generate AZT-resistant mutants 
(unpublished results), as discussed earlier. Using flow cytometric cell sorting coupled with a 
semi-quantitative PCR assay for detection of HIV-1 DNA, it was shown that most of the 
thymocytes within the HIV-1 infected Thy/Liv organ with induced DNA strand breaks in the 
chromosome were not infected with HIV-1. Thus, both cells with DNA strand breaks and 
without DNA strand breaks were infected at the same level (about 10% as measured by 
PCR). Therefore, HIV-1 replication may induce changes in the thymus to cause cell death 
(or chromosomal breakages) of uninfected, as well as infected, thymocytes.35 Likewise, it 
has been recently reported that most apoptotic cells are not productively infected in lymph 
nodes from HIV-1 infected human patients or from SIV infected monkeys.48
What contributes to the thymus depletion following HIV-1 infection?
Both direct and indirect mechanisms of cell death induction may be involved. The plateau 
and slight reduction of HIV-1 replication during thymus depletion may be interpreted as 
gradual depletion of direct HIV-1 target cells (Figure 2).24,35 Thus, HIV-1 infects and 
depletes the target cells and leads to lower levels of HIV-1 replication. Reduced replication 
may be achieved by a number of HIV-1 encoded factors with cytotoxic or cytostatic 
activities as demonstrated in T cells cultured in vitro. For example, vpr has been shown to 
lead to G2/S phase cell cycle arrest in infected target cells by a cytostatic mechanism.50 
Other HIV-1 proteins, such as tat, nef and gp120/gp41, have also demonstrated cytotoxic 
activity in various cell culture systems.51–54
Besides evidence discussed above of DNA strand breaks in uninfected cells, there is also 
evidence showing that, at least in some infected thymocytes, HIV-1 infection does not lead 
to their immediate destruction. For example, CD3+CD8+CD4− cells from HIV-1 infected 
Thy/Liv organs have been shown to carry HIV-1 proviral DNA 23,34 (Su, unpublished 
results). It has recently been shown that the HIV-1+ CD8 single positive cells are derived 
from HIV-1 infected CD4+ progenitors,55 possibly CD4+CD8+ and/or CD3−CD4+CD8− 
cells. Thus, HIV-1 infection of CD4+CD8+, CD3−CD4+CD8− or earlier progenitor cells 
does not necessarily lead to their immediate cytolysis.
Is thymocyte depletion due in part to destruction of intrathymic T progenitor cells?
Besides the CD4+CD8+ immature thymocytes, the intrathymic CD3−CD4+CD8− T 
progenitor cell subpopulation constitutes a target for HIV-1 infection in vivo. Some HIV-1 
isolates infect this population and deplete it; others infect it and do not lead to its immediate 
depletion.35 As illustrated in Figure 3, infection of progenitor cells by HIV-1 may lead to the 
following: (1) generation of a reservoir to transmit the HIV-1 genome to progeny cells; (2) 
destruction of a population that could provide progeny cells (reduction of progenitor cell 
pool); and (3) introduction of a maturational block upon normal thymocyte differentiation 
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processes. Induction of cell death, either by direct or indirect mechanisms, may occur 
through pathway a or pathway b (Figure 3).
In addition to production of viral proteins, HIV-1 infection also leads to cytokine 
dysregulation in humans.56 A large number of cytokines are produced in the thymus which 
play important roles in modulating T cell development. HIV-1 infection in the Thy/Liv 
organ leads to increased production of cytokines such as IL4, IL6, IL10. In addition, TNFa 
and TGFfl are also induced.57 The contribution of the increased levels of cytokines to 
thymocyte depletion is not clear and needs future attention. These viral and host ‘virulence 
factors’ may cause thymocyte depletion either directly or indirectly by enhancing HIV-1 
replication, as shown in pathway c (Figure 3).
The thymus microenvironment is essential for T cell development. Direct infection and 
destruction of thymic epithelium cells have been reported in the human thymus and in 
HIV-1 infected Thy/Liv organs.5,34 This may lead to blockage in T cell development and 
result in thymocyte death. Thus, HIV-1 infection of the Thy/Liv organ may cause 
destruction of the thymus microenvironment to induce thymocyte depletion (pathway d, 
Figure 3). It is not clear, however, whether the HIV-1 infected thymic stromal cells are still 
functional in supporting de novo human T cell development.
SCREENING ANTI-HIV-1 DRUGS IN THE SCID-HU MODEL
As mentioned above, the Thy/Liv model provides an in vivo system to study the human 
thymus organ in a normal, physiologically relevant state. In addition, the SCID-hu mouse 
also provides an animal model to test toxicity and bioavailability of therapeutic 
compounds.58 The SCID-hu Thy/Liv model has been used to evaluate anti-retroviral drugs 
since the beginning of its construction. AZT, either administered before or post exposure to 
HIV-1, appeared to inhibit HIV-1 replication in the model.32,59 In recent years, the Thy/Liv 
model has been used to evaluate and screen various compounds for their efficacy, toxicity 
and in vivo formulations.60,61 This includes AZT, didanosine, nevirapine and bicyclams 
(singly or in combinations). This will provide useful preclinical information in drug 
evaluation and clinical trials.
Novel peptide-based therapeutic agents can also be tested in this model. It has been reported 
that IL10, but not IL12, can inhibit HIV-1 replication in the SCID-hu Thy/Liv mouse.25
PRECLINICAL STUDIES OF HSC-BASED GENE THERAPY OR CELL 
THERAPY FOR AIDS
Gene delivery via the haematopoietic stem cell (HSC) offers an attractive means to 
introduce antiviral genes into both T cells and macrophages for AIDS gene therapy. HSC 
can be isolated from a number of tissue sources, including bone marrow and peripheral 
blood, and are used to reconstitute all haematopoietic lineages in transplant recipients.62,63 
Recently, haematopoietic progenitor cells have been efficiently transduced with murine 
leukaemia virus-based vectors.64,65 In addition, a retroviral vector encoding an anti-HIV-1 
ribozyme has been shown to inhibit HIV replication in macrophage-like cells derived from 
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the transduced stem/progenitor cells.65 Due to the difficulty of deriving human T cells from 
HSCs in vitro, it is difficult to demonstrate efficacy in the T lineage. The SCID-hu Thy/Liv 
model offers an ideal system to evaluate the potential of HSC-based gene therapy for AIDS.
The HIV-1 rev protein is critically required for the transport of unspliced HIV-1 mRNA into 
the cytoplasm and thus for the expression of HIV structural proteins.66 A trans-dominant 
mutant of HIV-1 rev, RevM10, has been shown to inhibit HIV-1 replication in PBMCs 
without affecting the growth and functions of the transduced cells.67,68 A clinical trial using 
retrovirally modified PBMCs, however, has demonstrated that RevM10 modified PBMC are 
short-lived in vivo. Thus, HSC-based gene therapy may be necessary to obtain long 
termanti-HIV-1 PBMCs in AIDS patients. It was unknown, however, whether the 
transduced gene will express at sufficient levels in T and myeloid cells and what effect (if 
any) RevM10 expression may have on the ability of transduced HSCs to differentiate into 
lymphoid or myeloid lineages.
To address these issues, experiments were performed to show that RevM10 could be 
efficiently transduced into cord blood derived HSC/progenitor cells, which develop into 
primary T cells69 or myeloid cells expressing the RevM10 gene in the SCID-hu Thy/Liv 
model or SCID-hu Bone model,70 respectively. After reconstitution of the Thy/Liv implants 
in SCID mice (SCID-hu Thy/Liv) with the transduced HSC/progenitor cells, normal 
thymocytes were derived and a significant number of donor derived thymocyte cells were 
found to express the RevM10 gene69 or a marker gene.71 It was further demonstrated that 
sufficient levels of RevM10 expression could be achieved to suppress HIV-1 replication in 
primary T cells derived from retrovirally transduced human HSCs69 Thus, the RevM10 gene 
did not appear to inhibit the differentiation of HSC/progenitor cells into T cells in the 
Thy/Liv organ. The level of retrovirus-mediated RevM10 expression in T cells derived from 
transduced HSCs was sufficient to suppress HIV-1 replication.
CONCLUSIONS
I have briefly summarised the most recent findings in HIV-1 infection and therapy using the 
SCID-hu Thy/Liv mouse. Its application to understanding HIV-1 infection, pathogenesis and 
therapy has proven that insighful information can be obtained about the HIV-1 disease 
process in vivo and about the feasibility of various therapeutic modalities. Further studies for 
assessing HIV-1 effects on the thymus environment, mechanisms of HIV-1 replication and 
associated thymocyte depletion, as well as tests of novel therapeutic agents and protocols are 
being explored by an increasing number of research groups. The preclinical studies of HSC-
based gene therapy in the SCID-hu mouse have helped to launch a Phase I/II clinical trial in 
HIV-1 infected patients (SyStemix, Inc., 1997).
A number of improved SCID-hu models have been constructed to meet different 
requirements. For example, human fetal liver, thymus, bone and spleen fragments have been 
co-transplanted into SCID mice to form a human joint organ with T cell, B cells, myeloid 
cells and red blood cells.72 This model will be useful to test HIV-1 pathogenesis and to 
study HSC differentiation into all lineages in the same organ. In addition, implanting human 
lung tissues intraperitoneally in the SCID-hu Thy/Liv mouse has created a model to study 
Su Page 7













HIV-1 infection of the lung (macrophages) and its transmission to the Thy/Liv organ.26 
Using current or improved SCID-hu Thy/Liv models, future efforts are directed to 
addressing the following outstanding questions.
1. What viral factors (virulence factors) are uniquely required for replication and/or 
pathogenicity in the Thy/Liv organ?
2. What host factors are involved in HIV-1 induced thymus depletion?
3. What are the distributions of co-receptors (CCR5 and fusin) in the Thy/Liv organ?
4. What target cells are infected in the Thy/Liv organ by different HIV-1 isolates?
5. How significant is HIV-1 induced indirect cell killing in the Thy/Liv model?
6. Can HIV-1 infected/depleted Thy/Liv organs still support de novo thymopoiesis 
from HSC/progenitor cells carrying an antiviral gene or in the presence of antiviral 
drugs?
7. Are the findings of studying SCID-hu Thy/Liv mice reflective of HIV-1 infection 
in humans (paediatric infection in particular)?
Answers to these questions will further prove the usefulness of the model and provide 
insightful information for understanding pathogenesis and designing therapeutic 
interventions against HIV-1 infection in humans, especially in paediatric patients.
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HIV-1 infection of the SCID-hu Thy/Liv mouse. Human fetal thymus and liver fragments 
transplanted under renal capsules in SCID mice support stable human thymopoiesis for over 
a year. HIV-1 inoculation and endpoint (1–6 wpi) analyses are illustrated.
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Kinetics of HIV-1 replication and pathogenesis in the Thy/Liv organ. (A) Production of viral 
p24 antigen after HIV-1 infection. Thymocyte-associated p24 antigen is measured and 
standardised as pg/106 cells). NL4–3 is a T-tropic HIV-1 clone. EW and JD are two primary 
patient isolates. No Thy/Liv organs infected by JD are analysed at 5 wpi. NC: Negative 
controls of mock infected Thy/Liv organs. (B) Depletion of CD4+CD8+ thymocytes after 
HIV-1 infection. SCID-hu mice are analysed by FACS staining of CD4 and CD8. 
%CD4+CD8+, which consist of 80%–85% of total thymocytes in normal human thymi and 
Thy/Liv organs, is a good measure of thymocyte depletion.
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A model for multiple target cells and pathogenic pathways of HIV-1 pathogenesis in the 
human thymus. HIV-1 infection may occur in many different types of cells in the thymus 
(both thymocytes and stromal cells). Infection and destruction of intrathymic T progenitor 
cells will block the supply of new thymocyte maturation, leading to thymus depletion 
(pathway a). Direct infection of CD4+ thymocytes may lead to their destruction (pathway b). 
In addition, virulence factors induced after HIV-1 infection may directly induce thymocyte 
death or indirectly by enhancing HIV-1 replication in the thymocytes (pathway c). 
Furthermore, destruction of thymic stromal cells following HIV-1 infection may contribute 
to thymocyte death induction (pathway d). HSC: haematopoietic stem cell. TN: Triple 
negative (CD3−CD4−CD8−) thymocytes.
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Preclinical studies of HSC-based gene therapy in the SCID-hu Thy/Liv model. Retroviral-
modified HSC/progenitors can be used to reconstitute the Thy/Liv organ which is irradiated 
to deplete resident thymocytes. Donor cells can be identified by mismatched HLA markers 
or by retroviral marking. Thymocytes from reconstituted Thy/Liv organs can be isolated and 
characterised in vitro to study gene expression, T cell function and resistance to HIV-1 
infection.
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 NL4–3 +++ +++ +++
 NL4–vif − 
d +/− +/−
 NL4–vpr +++ ++ ++
 NL4–vpu +++ + +
 NL4–nef +++ +/− +/−
 JRCSF +++ ++ ++
 JRCSF-nef +++ + NDS
e
 Lai/IIIB +++ − −
 HXB2 +++ − −
 HXB2/LW +++ +++ NDS
Primary isolates
 SM +++ +++ +++
 TY +++ +++ +++
 EW +++ +++ +++
 JD +++ +++ +++
 A–NSI + +/− +/−
 A–SI +++ +++ +++
 B–NSI + +/− +/−
 B–SI +++ +++ ++
 LTNP–NSI + +/− +/−
Data from the following reports are summarised. NL4–323,33,35,39,40,43 and its mutant derivatives,39,40 JRCSF23,24,33,34,39 and JRCSF–
nef,39 Lai/IIIB31 HXB2 and HXB2/LW.31,43 SM,24,34 TY24 EW24,35 JD35 A–NSI, SI and B–NSI, SI.36 LTNP (long-term non-progressor)–
NSI.37
a
Replication in PHA-activated PBMC as measured by p24 or RT production.
b
HIV-1 replication in the Thy/Liv organ measured by cell- associated p24 or by semi-quantitative DNA PCR analyses.
c
Thymocyte depletion after HIV-1 infection as analysed by FACS analysis.
d
NL4–vif mutant replicates in certain T cell lines.
e
No data shown.
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